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Purpose: To evaluate retinal toxicity of varying doses of rapamycin when
injected intravitreally in rabbits. Rapamycin is a potent immunosup-
pressive agent with significant antitumor and antiangiogenic properties,
clinically approved for prevention of organ transplant rejection. Methods:
Twelve New Zealand albino rabbits were divided into four groups. Four
different doses of rapamycin were prepared in 0.1 ml: 20 μg, 50 μg, 200 μg,
and 1000 μg. Each concentration was injected in one eye of three rabbits,
and 0.1 ml volume of sterile BSS was injected into the contralateral eye of
the three rabbits. Slit-lamp and fundoscopic examinations were perfor-
med and the animals were observed for 2 weeks for signs of infection,
inflammation, and toxicity. A baseline ERG was performed before drug
treatment and at day 14, after which the rabbits were euthanized. Histology
of the enucleated eyes was studied to look for retinal toxicity. Results:
ERG results showed some decrease in scotopic response; however this
was not dose related. ERG results were normal at 20 μg. Histological
results showed no retinal toxicity in all groups. Conclusion: Although
ERG changes were identified at dosages between 50-1000 μg, the histology
of all groups up to 1000 μg did not show any discernable abnormalities.
ABSTRACT
INTRODUCTION
Treatment of severe ocular inflammation may require long-term use of
immunosuppressive drugs. Long-term use of these drugs is problematic
because of their adverse side effects. To decrease these adverse side
effects, intravitreal administration is a possible treatment option.
Rapamycin (sirolimus; A.G. Scientific, San Diego, CA) is a cyclic ma-
crolide antibiotic isolated from the fungus Streptomyces hygroscopicus(1).
It is a potent immunosuppressive agent, clinically approved for prevention
of organ transplant rejection(2). It has been used in sirolimus eluting stents
in patients with coronary artery disease(3), as it also has antiproliferative
effects on smooth muscle cells and on arterial intimal thickening(4). Similar
to cyclosporine and tacrolimus, it is an inhibitor of T cell activation.
However, it has no effect on the calcineurin/calmodulin complex and binds
to intracellular receptors known as immunophilins. Rapamycin inhibits two
protein kinases-termed the mammalian target of rapamycin (mTOR 1 and
mTOR 2) - associated with cell cycle progression in the G1 phase. Rapa-
mycin interferes with cell cycle progression in a later stage than cyclos-
porin and FK 506, blocking not the proliferation-stimulating factors but the
proliferation signal that is induced by these factors(5).
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Rapamycin has significant antitumor and antiangiogenic
activities. Several rapamycin-related compounds are in phase
I, II and III clinical trials in patients with renal cancer and other
malignancies(6). In an in vivo experiment with rats, rapamycin
dramatically inhibited tumor growth, with a marked decrease in
tumor vascularization(7). Guba et al. demonstrated the anti-
VEGF activity of sirolimus in a murine tumor model(8). Its
antiangiogenic properties were also demonstrated in a 1995
study by Olsen et al. who showed that rats receiving sirolimus
following orthotopic allogenic corneal grafts had reduced
amounts of corneal neovascularization(9). Recently, it was
demonstrated that rapamycin significantly reduced the extent
of neovascularization in both experimental choroidal neovas-
cularization (CNV) and retinopathy of prematurity (ROP) in
mice(10).
 Rapamycin has been shown to reduce inflammation in
animal models of experimental autoimmune uveitis, in combi-
nation with tacrolimus and cyclosporine(11-12). Recent inves-
tigation has revealed that rapamycin is an effective and potent
immunosuppressive treatment for patients with non-infec-
tious uveitis and can reduce the need for long-term supple-
mentary corticosteroid therapy(13).
One possible option of treatment for chronic non-infec-
tious uveitis, choroidal, or retinal neovascularization could be
an intravitreal injection of rapamycin based on its immuno-
suppressive and antiangiogenic properties. However, retinal
toxicity is a primary concern when using intravitreal injec-
tions. The purpose of our study was to analyze the retinal
toxicity of rapamycin at various doses.
METHODS
Animals
Twelve New Zealand albino rabbits weighing between 2
and 3 kg were used for this study. The rabbits were treated
according to guidelines of the Association for Research in
Vision and Ophthalmology (ARVO). Slit-lamp and indirect
fundoscopic examinations were performed on all eyes prior to
the study and on days 1, 7, and 14 after intravitreal injection.
Any rabbit that demonstrated corneal or lens opacity or retinal
damage prior to the study was excluded. Rabbits were anes-
thetized before all procedures using approximately 1 ml of a
mixture of ketamine hydrochloride (50 mg/kg) and xylazine
hydrochloride (5 mg/kg). The eyes were dilated by topical
application of phenylephrine (2.5%) and tropicamide (0.5%).
Topical anesthesia was applied using proparacaine (0.5%).
Intravitreal injections
All procedures were performed under sterile conditions
using an operating microscope for visualization. Anterior cham-
ber tap was performed with a 25 G needle withdrawing 0.1 cc of
aqueous fluid to reduce intraocular pressure and to minimize
drug reflux following injection. Intravitreal injection was per-
formed using a 30 G needle attached to a tuberculin syringe
inserted bevel up approximately 2 mm posterior to the limbus.
Four different doses of rapamycin were prepared in 0.1 ml: 20 μg,
50 μg, 200 μg, and 1000 μg. Each dose was injected in one eye
of three rabbits, and 0.1 ml volume of sterile BSS was injected
into the contralateral eye of the three rabbits. Slit-lamp and
fundoscopic examinations were performed and the animals
were observed for 2 weeks for signs of infection, inflammation,
and toxicity.
Electrophysiological tests
ERG using the UTAS-2000 system (LKC Technology,
Gaithersburg, MD) was performed prior to and 14 days after
intravitreal injection. Rabbits were dark-adapted for at least
30 minutes after pupillary dilation. Unipolar contact lenses
(ERG jet electrodes) were put on both corneas with Goniosol
(IOLab Corporation, Claremont, CA); the negative electrode
was placed in the subcutaneous space of the forehead, and
the ground electrode was clipped to the earlobe with some
electric gel. The dark-adapted scotopic response (step 1, Rod
response), scotopic flash response (step 2, Maximal response,
cone+ rod) and (after waiting 3 minutes) light-adapted pho-
topic response (step 4, Cone response) were recorded. The
average of five sweeps was determined for each step. The
difference between a and b waves was calculated for each
step. The baseline was compared to the response 2 weeks
after injection.
Histological examination
Following the final ERG session, all rabbits were eutha-
nized with an intravenous injection of sodium pentobarbital.
The eyes were enucleated and fixed in Karnovsky fixative for
48 hours and then processed, sectioned, and stained with
hematoxylin and eosin for light microscopy.
RESULTS
Clinical examination
No corneal opacity, cataract, vitreous hemorrhage, retinal
detachment, or optic atrophy was seen in any of the rabbit
eyes by fundoscopic examination.
Electrophysiological tests
Follow-up ERGs showed some decrease in 2 of 3 eyes va-
rying in the amplitude of the following groups: 50 μg, 200 μg,
and 1000 μg. However, this decrease was not dose related and
was never extinguished (Figures 1, 2).
Histological examination
Histological examination of the eyes and retinas showed
no toxic damage; in particular there was no necrosis, gliosis,
degeneration of photoreceptors or neurons, retinal detach-
ment, or inflammation in any of the eyes examined at any
dosage (Figures 3, 4).
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Figure 1 - ERG step 1, 2, and 4 of one rabbit eye before (left) and 14 days after (right) intravitreal injection of 200 μg rapamycin. There is a decrease
in the amplitude of step 1.
Figure 2 - ERG step 1, 2, and 4 of one rabbit eye before (left) and 14 days after (right) intravitreal injection of 1000 μg rapamycin. There is a non-
significant decrease in step 1 and 2, and an increase in amplitude in step 4.
Figure 3 - Normal retinal histology in rabbit eye after intravitreal
injection of 200 μg rapamycin (H&E stain)
Figure 4 - Normal retinal histology in rabbit eye after intravitreal
injection of 1000 μg rapamycin (H&E stain)
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DISCUSSION
Rapamycin appeared to be non-toxic to the retina in albino
rabbits; however, we observed some decrease in ERG amplitu-
de, mainly in the scotopic response in a few eyes. The ERG
findings were not uniform in each group nor were they dose
related. We think this finding might have been related to
reduced body temperature occurring in a cold room in anes-
thetized animals during dark adaptation(14-15). Hypothermia
decreases general body metabolism, leading to a reduction in
the rate of chemical reactions and the amplitude of the ERG in
mice and rabbits(14-15).
Another possibility for this slight decrease in the a-wave
amplitude is that rapamycin (a lipophilic compound) might be
localized in the region of photoreceptor or a pigment epithe-
lium, thus creating some dysfunction of the photoreceptor.
Further studies including immunohistochemical assays of
drug localization should be done to confirm this possibility.
Maybe the histology is not sensitive enough since doses
below 50 μg did not cause any ERG changes. We can have
some functional damage without any change in the histology.
Nevertheless, normal ERG does not rule out functional and
possible structural changes at the level of ganglion cells or
the nerve fiber layer. The lack of changes by light microscopy
does not exclude possible alterations at a submicroscopic
level. Further studies must be done to evaluate this possi-
bility.
An important characteristic of rapamycin is its antiangio-
genic property.
Numerous clinical and experimental observations have in-
dicated that ischemia or hypoxia triggers retinal neovascula-
rization through an excessive production of angiogenic factors.
Among multiple factors, many investigators have reported vas-
cular endothelial growth factor (VEGF) to be an important(16-17)
and major stimulus responsible for neovascularization in exu-
dative age-related macular degeneration (ARMD)(18).
Intravitreal injections of VEGF inhibitors such as pegap-
tanib(19-20), ranibizumab(21-22), and bevacizumab(23) have been
commonly used to treat CNV.
Intravitreal injection of rapamycin may have a potential in
the treatment of CNV in ARMD. The antiangiogenic proper-
ties of rapamycin are associated with a decrease in VEGF
production and a reduction in the response of vascular en-
dothelial cells to stimulation by VEGF(8). The mechanism by
which rapamycin elicits its effects is not clear. mTOR is an
upstream activator of hypoxia inducible factor 1α (HIF-1α), a
transcription factor that mediates the transcriptional regula-
tion of VEGF(24-25). In hypoxic cells, rapamycin can interfere
with HIF-1α activation by increasing the rate of its degrada-
tion(24).
Other proangiogenic agents such as basic fibroblast growth
factor (bFGF), platelet derived growth factor B (PDGF-B), nitric
oxide synthase, and angiopoietin are upregulated by hypo-
xia(26). Hypoxia can stimulate gene expression by different me-
chanisms including gene transcription, regulation at the trans-
lational level, and mRNA stabilization. Rapamycin affects mTOR,
thereby influencing all these pathways(5,27). Therefore, rapamy-
cin may also be exerting its effects through additional non-
VEGF related pathways.
Our study showed that rapamycin did not cause any
histologic changes to the rabbit retina when injected intra-
vitreally up to a concentration of 1000 μg. Further studies are
warranted to evaluate the long-term safety of high doses of
this drug. Intravitreal rapamycin may offer another option for
the treatment of CNV in ARMD, retinal neovascularization,
and chronic uveitis.
RESUMO
Objetivo: Avaliar a toxicidade da injeção intravítrea de dife-
rentes doses de rapamicina para a retina de coelhos. Rapami-
cina é uma potente droga imunossupressora aprovada clinica-
mente para a prevenção da rejeição de transplantes de orgãos.
Métodos: Doze coelhos albinos da Nova Zelândia foram usa-
dos neste estudo. Foram divididos em quatro grupos. Quatro
diferentes doses de rapamicina foram preparadas nas seguin-
tes concentrações: 20 μg, 50 μg, 200 μg, 1000 μg. Foram rea-
lizadas injeções intravítreas de 0,1 ml de cada concentração em
um olho de três coelhos e 0,1 ml de solução salina foi injetada
no olho contralateral de cada coelho. Foram realizadas bio-
microscopia e fundoscopia e observamos sinais de inflama-
ção, infecção ou toxicidade durante duas semanas. Fizemos
um ERG antes do tratamento e outro 14 dias depois da injeção
intravítrea. Os animais foram sacrificados, fizemos a enuclea-
ção dos olhos e preparamos o tecido para a avaliação histo-
lógica. Resultados: Os resultados do ERG e da histologia
demonstraram diminuição da resposta escotópica, entretanto
essa diminuição não foi dose dependente. A histologia foi
normal em todos os grupos. Conclusão: A injeção intravítrea
de rapamicina levou a alterações eletrorretinográficas nos gru-
pos de 50-1000 μg, entretanto a histologia foi normal em todos
os grupos até 1000 μg.
Descritores: Neovascularização coroidal; Sirolimo/toxici-
dade; Uveite; Receptor 1 do fator de crescimento do endotélio
vascular; Coelhos
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